Recombinant Mouse RNASE3 Protein，His

Recombinant RNASE3, also known as eosinophil cationic protein (ECP), has garnered significant attention due to its potential therapeutic applications and its role in immune responses, particularly in allergic diseases and asthma. RNASE3 is primarily produced by eosinophils, a type of white blood cell that plays a crucial role in the body's defense against parasitic infections and in mediating allergic reactions. The protein exhibits ribonucleolytic activity, enabling it to degrade RNA, which is significant for its antimicrobial properties. This characteristic has spurred research into its use as an antiviral agent and in cancer therapy, where targeted RNA degradation could inhibit tumor growth. Moreover, understanding the structure-function relationship of RNASE3 is vital for engineering variants with enhanced activity or specificity. The production of recombinant RNASE3 allows for detailed studies of its biochemical properties and its interactions with other molecules in the immune system. This not only aids in elucidating the mechanisms underlying eosinophil-related pathologies but also facilitates the development of potential therapeutic interventions, providing insights into novel treatments for conditions such as asthma and other allergic diseases. Given the increasing incidence of such conditions globally, RNASE3 represents a promising avenue for future research and development.